RxDoctor Payments DataLook up a doctor →

Kimberly Adams, MD

Family Medicine · Las Vegas, NVNPI 1659399269

Payments from drug & device makers

$51,206in general payments, 2019–2025

Across 727 payments — averaging $70.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$36K
  • Intuitive Surgical$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Amgen$969
  • plus $7K from 52 others

What the payments were for

  • Speaking & faculty fees$31,35061%
  • Travel & lodging$6,18712%
  • Food & beverage$13,56226%
  • Education$1080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,206 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$94,446
Medicare patients
214
Services billed
1,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide325$416,627
OzempicSemaglutide130$158,453
EliquisApixaban56$48,208
VraylarCariprazine Hcl24$42,784
Diclofenac Sodium42$24,264
XareltoRivaroxaban24$20,927
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$20,537
JardianceEmpagliflozin17$18,777
Tresiba Flextouch U-100Insulin Degludec19$17,328
TrulicityDulaglutide15$16,208
Praluent PenAlirocumab19$13,233
Breo ElliptaFluticasone/Vilanterol31$12,203
Repatha PushtronexEvolocumab17$12,019
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,051
LinzessLinaclotide15$8,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$36,285$432,835340 claims
Novo NordiskOzempic$1,187$158,453130 claims
AbbVieVraylar, Linzess, Synthroid$2,129$56,40793 claims
PfizerEliquis, Prempro$894$51,89372 claims
GSKBreo Ellipta, Trelegy Ellipta$49$21,25445 claims
Johnson & JohnsonXarelto$65$20,92724 claims
AstraZenecaBreztri Aerosphere$1,463$20,53726 claims
Boehringer IngelheimJardiance$81$18,77717 claims
Astellas Pharma US IncVeozah$267$6,96113 claims
Antares Pharma, Inc.Xyosted$48$6,68811 claims
Almatica Pharma LLCSertraline Hcl$13$1,480239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →